Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2021
Filed with the SEC on Feb 9, 2022 and accepted by EDGAR at Feb 9, 2022, 16:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-01-01 to 2021-12-31 | $7.57bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2021-01-01 to 2021-12-31 | $904.2m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2021-01-01 to 2021-12-31 | $3.05bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2021-01-01 to 2021-12-31 | $840.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2021-01-01 to 2021-12-31 | $2.78bn | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2021-01-01 to 2021-12-31 | $388.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2021-01-01 to 2021-12-31 | $2.34bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2021-01-01 to 2021-12-31 | $9.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2021-01-01 to 2021-12-31 | $9.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2021-01-01 to 2021-12-31 | 259,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2021-01-01 to 2021-12-31 | $2.64bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2021-01-01 to 2021-12-31 | $235.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2021-01-01 to 2021-12-31 | $1.43bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2021-12-31 | $6.79bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-12-31 | $9.56bn | us-gaap:AssetsCurrent |
| Total assets | At period end2021-12-31 | $13.43bn | us-gaap:Assets |
| Current liabilities | At period end2021-12-31 | $2.14bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-12-31 | $3.33bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-12-31 | $10.10bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-22-000007. Last ingested by Listed: Nov 3, 2026, 18:50 ET. Listed shows no prices and gives no investment advice.